Announcement on Subsidiary's Vecuronium Bromide for Injection Passing Generic Drug Consistency Evaluation
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Subsidiary's Vecuronium Bromide for Injection Passing Generic Drug Consistency Evaluation
Filed with SSE · · 3 pages · Chinese
Release
Lionco Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Lionco Pharmaceutical
- Announcement on the Optional Reselling Results of "Lionco Convertible Bonds"
- The 9th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
- The 8th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
- The 7th Indicative Announcement on Optional Sell-back of "Lionco Convertible Bonds"
Later from Lionco Pharmaceutical
- Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2025 and Providing Corresponding Guarantee
- Report for Q1 2025
- Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Wholly-owned Subsidiary
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Early Return of Raised Funds for Temporary Supplement to Current Capital
Follow Lionco Pharmaceutical into a list and get an email when it puts out news.
Follow Lionco Pharmaceutical